Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 3/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760527 | 1.00 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL8270806 | 1.00 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3184303 | 0.87 | CA1 (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3184315 | 0.87 | CA1 (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3184308 | 0.87 | CA1 (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3184297 | 0.87 | CA1 (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL13413126 | 0.86 | CA1 (0.39) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3185350 | 0.86 | REN (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3185341 | 0.86 | REN (0.34) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL3185355 | 0.86 | REN (0.34) | CA1CA2CA7CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919021-B2 | Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions | IBET—INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA (PT) | 2018-03-20 | — | — | US | disclosed |
| US-20170296618-A1 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS | IBET - INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA (PT) | 2017-10-19 | — | — | US | disclosed |
| US-7829669-B2 | Catalytically active recombinant memapsin and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| EP-1194449-B1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MED RES FOUND (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7678760-B2 | Inhibitors of Memapsin 2 and use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-16 | — | — | US | disclosed |
| US-7659289-B2 | Hydroxyethylene-based β-secretase inhibitors and use thereof | COMENTIS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659289-B2 | Hydroxyethylene-based β-secretase inhibitors and use thereof | COMENTIS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-6545127-B1 | Alzheimer*s disease; amyloid precursor protein | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-04-08 | — | — | US | disclosed |
| US-20020164760-A1 | Catalytically active recombinant memapsin and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2002-11-07 | — | — | US | disclosed |
| US-5364844-A | Hypotensive agents | SANKYO COMPANY, LIMITED (JP) | 1994-11-15 | — | — | US | disclosed |
| EP-0326364-B1 | Renin inhibitory oligopeptides, their preparation and use | SANKYO CO (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0212903-B1 | POLYPEPTIDE DERIVATIVES CONTAINING 5-AMINO-2,5-DISUBSTITUTED-4-HYDROXYPENTANOIC ACID RESIDUES | PFIZER INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-4992562-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4948913-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0326364-A2 | Renin inhibitory oligopeptides, their preparation and use | Sankyo Company Limited (JP) | 1989-08-02 | — | — | EP | disclosed |
| US-4729985-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0212903-A2 | Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE2, BACE1, PSEN2 | CA1 785/4885CA2 2737/4885CA7 4230/4885 |
| US-20170296618-A1 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS | BACE1, BACE2, APP | CA1 920/4885CA2 3608/4885CA7 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.